Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.

"Conflicts of Interest EVL reports grants and personal fees from Gilead Sciences, Inc. [Gilead] during the conduct of the study; grants from Receptos, Robarts Clinical Trials, and Theravance; grants and personal fees from AbbVie, Amgen, Bristol Myers Squibb [BMS], Celgene, Genentech, Gilead, Gossamer Bio, Janssen, Pfizer, and Takeda; and personal fees from Allergan, Arena, Boehringer Ingelheim, Calibr, Iterative Scopes, Lilly, Morphic Therapeutic, Ono Pharma, Protagonist Therapeutics, Scipher Medicine, Sun Pharma, and Surrozen, outside the submitted work. SV reports grants from AbbVie, Galapagos, Johnson & Johnson [J&J], Pfizer, and Takeda; and consultancy fees from AbbVie, Abivax, Arena Pharmaceuticals, Avaxia, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech/Roche, Gilead, GlaxoSmithKline [GSK], Hospira, Janssen, Mundipharma, MSD, Pfizer, ProDigest, Progenity, Prometheus, Robarts Clinical Trials, Second Genome, Shire, Takeda, Theravance, and Tillotts Pharma AG, outside the submitted work. BGF reports grants and personal fees from AbbVie, Amgen, AstraZeneca, BMS, Janssen Biotech/Centocor, J&J/Janssen, Pfizer, Receptos, and Takeda; and personal fees from Ablynx, ActoGeniX, AdMIRx, Inc., Akebia Therapeutics, Inc., Allergan, Atlantic Pharma, Avaxia Biologics, Inc., Avir Pharma, Baxter Healthcare Corporation, Biogen Idec, BiomX Israel, Boehringer Ingelheim, Boston Pharmaceuticals, Calypso Biotech, Celgene, Elan/Biogen, enGene, Ferring, Galapagos, Genentech/Roche, gIcare Pharma, Gilead, Given Imaging, Gossamer Pharma, GSK, Inception IBD, Inc., Ironwood, Japan Tobacco Company, Kyowa Hakko Kirin Co. Ltd, Lexicon, Lilly, Lycera Biotech, MSD, Mesoblast, Millennium, Nestlé, Nextbiotix, Novartis, Novo Nordisk, Par’Immune, Progenity, Prometheus Therapeutics & Diagnostics, Protagonist, Qu Biologics, Salix, Shire, Sienna Biologics, Sigmoid Pharma, Synergy Pharma, Teva Pharmaceuticals, TiGenix, Tillotts, UCB, Vertex, VHsquared, Vivelix Pharmaceuticals, Wyeth, Zealand, and Zyngenia, outside the submitted work. FOLB and AO are employees and shareholders of Galapagos. UM is an employee and shareholder of Gilead. WJS reports research grants from AbbVie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead, GSK, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda, and Theravance Biopharma; consulting fees from AbbVie, Abivax, Admirx, Alfasigma, Alimentiv [previously Robarts Clinical Trials, owned by Alimentiv Health Trust], Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health [Salix], Beigene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, BMS, Celgene, Celltrion, Cellularity, Cosmo Pharmaceuticals, Escalier Biosciences, Equillium, Forbion, Genentech/Roche, Gilead, Glenmark Pharmaceuticals, Gossamer Bio, Immunic [Vital Therapies], Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma [acquired by Ventyx Biosciences], Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals, Tillotts Pharma, UCB, Vendata Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, Vivreon Biosciences, and Zealand Pharma; stock or stock options from Allakos, BeiGene, Gossamer Bio, Oppilan Pharma, Progenity, Prometheus Biosciences, Prometheus Laboratories, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, and Vivreon Biosciences; and is an employee at Shoreline Biosciences. WJS’s spouse: Iveric Bio—consultant, stock options; Progenity—stock; Oppilan Pharma—consultant, stock options; Prometheus Biosciences—employee, stock, stock options; Prometheus Laboratories—stock, stock options, consultant; Ventyx Biosciences—stock, stock options; and Vimalan Biosciences—stock, stock options. TH reports grants from Otsuka Holdings, grants and personal fees from AbbVie GK, JIMRO, Kyorin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical, and Zeria Pharmaceutical; and personal fees from Aspen Japan K.K., BMS, Celltrion, EA Pharma, Lilly, Ferring, Gilead, Janssen, Kissei Pharmaceutical, Nichi-Iko Pharmaceutical, Nippon Kayaku, and Pfizer, outside the submitted work."

"Funding The SELECTION trial was sponsored by Gilead Sciences, Inc. Galapagos NV was a collaborator for the SELECTION trial and funded this study."